A detailed history of Janus Henderson Group PLC transactions in Geron Corp stock. As of the latest transaction made, Janus Henderson Group PLC holds 22,565,846 shares of GERN stock, worth $91.2 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
22,565,846
Previous 9,401,957 140.01%
Holding current value
$91.2 Million
Previous $39.9 Million 156.99%
% of portfolio
0.05%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.17 - $4.99 $54.9 Million - $65.7 Million
13,163,889 Added 140.01%
22,565,846 $102 Million
Q2 2024

Aug 14, 2024

BUY
$3.1 - $5.09 $28.6 Million - $46.9 Million
9,220,920 Added 5093.39%
9,401,957 $39.9 Million
Q1 2024

May 15, 2024

BUY
$1.75 - $3.44 $33 - $65
19 Added 0.01%
181,037 $597,000
Q4 2023

Feb 14, 2024

SELL
$1.74 - $2.31 $508 - $674
-292 Reduced 0.16%
181,018 $381,000
Q3 2023

Nov 14, 2023

BUY
$2.11 - $3.28 $105 - $164
50 Added 0.03%
181,310 $384,000
Q2 2023

Aug 14, 2023

SELL
$1.97 - $3.69 $433 - $811
-220 Reduced 0.12%
181,260 $581,000
Q1 2023

May 15, 2023

BUY
$2.14 - $3.4 $282,614 - $449,014
132,063 Added 267.24%
181,480 $393,000
Q4 2022

Feb 14, 2023

SELL
$2.03 - $2.42 $36 - $43
-18 Reduced 0.04%
49,417 $119,000
Q3 2022

Nov 14, 2022

BUY
$1.67 - $2.94 $313 - $552
188 Added 0.38%
49,435 $116,000
Q2 2022

Aug 15, 2022

BUY
$1.19 - $1.65 $239 - $331
201 Added 0.41%
49,247 $76,000
Q1 2022

May 16, 2022

BUY
$0.99 - $1.6 $20 - $33
21 Added 0.04%
49,046 $67,000
Q4 2021

Feb 14, 2022

BUY
$1.22 - $1.72 $30,184 - $42,554
24,741 Added 101.88%
49,025 $60,000
Q3 2021

Nov 16, 2021

BUY
$1.2 - $1.5 $29,140 - $36,426
24,284 New
24,284 $33,000

Others Institutions Holding GERN

About GERON CORP


  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $1.53B
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.